NewLimit eyes clinic in 2027 Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 3 June, 2026

A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.

news Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases Anti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027 What’s next for VEGF? ASCO offered clues, but answers will have to wait

Jun 11 11:00 am ET Data-driven manufacturing: Enhancing process robustness across sites sponsored by Samsung Biologics

Senior Director, Licensing Officer Bayer Cambridge, MA, USA Director, Government Pricing Sandoz Princeton, NJ, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.

PHARMA Exclusive: Bipartisan group of lawmakers unveil new bill to restrict China biotech FDA details flexibilities for new cell and gene therapies to leverage past data Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti Lilly gives hospitals deadline to comply with 340B claims data policy Updated: Allen Institute launches $400M effort to turn brain atlas lessons into medicines

in case you missed it 1. Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis 2. Roche details narrow failure of breast cancer pill trial 3. Celcuity aims for broad FDA approval after positive breast cancer readout 4. Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit 5. Travere pays Everest $112M upfront to grow rare kidney disease pipeline 6. News Briefing Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3 7. Praxis sinks on late-stage study fail for seizure pill, halts second trial 8. US to re-engage with Gavi vaccine alliance amid Ebola outbreak, Rubio says